The mEHT method uses tissues’ thermal and bioelectromagnetic heterogeneity for the selective mechanisms. The success of the therapy for advanced, relapsed, and metastatic aggressive tumors can only be demonstrated by measuring survival time and quality of life (QoL). The complication is that mEHT-treated patients cannot be curatively treated any longer with “gold standards”, where the permanent progression of the disease, the refractory, relapsing situation, the organ failure, the worsening of blood counts, etc., block them. Collecting a cohort of these patients is frequently impossible. Only an intent-to-treat (ITT) patient group was available. Due to the above limitations, many studies have single-arm data collection. The Phase III trial of advanced cervix tumors subgrouping of HIV-negative and -positive patients showed the stable efficacy of mEHT in all patients’ subgroups. The single-arm represents lower-level evidence, which can be improved by comparing the survival data of various studies from different institutes. The Kaplan–Meier probability comparison had no significant differences, so pooled data were compared to other methods. Following this approach, we demonstrate the feasibility and superiority of mEHT in the cases of glioblastoma multiform, pancreas carcinomas, lung tumors, and colorectal tumors.
mEHT方法利用组织的热与生物电磁异质性实现选择性作用机制。该疗法对晚期、复发及转移性侵袭肿瘤的疗效只能通过生存时间和生活质量（QoL）的测量来验证。其复杂性在于，接受mEHT治疗的患者往往已无法再接受"金标准"根治性治疗——疾病的持续进展、难治性复发状态、器官衰竭、血象恶化等因素均构成治疗障碍。因此常难以收集到符合严格标准的患者队列，本研究仅能获得意向治疗（ITT）患者群体。受上述限制，多数研究仅能进行单臂数据收集。针对晚期宫颈癌的III期临床试验通过HIV阴性与阳性亚组分析显示，mEHT在所有患者亚组中均保持稳定的疗效。单臂研究提供的证据等级较低，但通过对比不同研究机构的生存数据可提升证据强度。卡普兰-迈耶概率比较显示无显著差异，故将汇总数据与其他疗法进行对比。基于此方法，我们证明了mEHT在多形性胶质母细胞瘤、胰腺癌、肺肿瘤及结直肠肿瘤病例中的可行性与优越性。
The Clinical Validation of Modulated Electro-Hyperthermia (mEHT)
肿瘤(癌症)患者之家